Abstract
MLN4924 is a first-in-class cancer drug that inhibits the Nedd8-activating enzyme (NAE). Herein, we report that MLN4924 inhibits Vpx/Vpr-induced SAMHD1 degradation by inhibiting the neddylation of E3 ubiquitin ligase and blocks macaque simian immunodeficiency virus (SIVmac) replication in myeloid cells. SAMHD1 is required for MLN4924-mediated SIVmac inhibition. Our findings indicate the potential efficacy of inhibiting neddylation as an antiretroviral strategy and identify the readily available anticancer drug MLN4924 as a candidate agent for that purpose.
Original language | English (US) |
---|---|
Pages (from-to) | 745-751 |
Number of pages | 7 |
Journal | Journal of virology |
Volume | 88 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2014 |
ASJC Scopus subject areas
- Microbiology
- Immunology
- Insect Science
- Virology